The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Non-immunological approaches being explored for the treatment of CLL
In this video, Jennifer Woyach, MD, The Ohio State University, Columbus, OH, briefly discusses the non-immunological approaches being explored for the treatment of chronic lymphocytic leukemia (CLL). Dr Woyach emphasizes the importance of targeting the underlying biology of CLL, which she believes will lead to more effective future therapies. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are a number of non-immunologic approaches that are really promising in CLL right now. I mean, first and foremost are novel therapies that are being investigated targeting either the B-cell receptor pathway with novel BTK inhibitors, other inhibitors of the BCR pathway, strategies that target the anti-apoptotic mechanisms of CLL, so other BCL2 inhibitors, things that target BCL2 and BCLxL or other members of those families, and as well surface antigens that can be targeted with either monoclonal antibodies, ADCs, bispecific antibodies...
There are a number of non-immunologic approaches that are really promising in CLL right now. I mean, first and foremost are novel therapies that are being investigated targeting either the B-cell receptor pathway with novel BTK inhibitors, other inhibitors of the BCR pathway, strategies that target the anti-apoptotic mechanisms of CLL, so other BCL2 inhibitors, things that target BCL2 and BCLxL or other members of those families, and as well surface antigens that can be targeted with either monoclonal antibodies, ADCs, bispecific antibodies. So there’s a lot of things that are really attacking the underlying biology of CLL that I think are going to help us in future therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting/Advisory: Pharmacyclics, Janssen, AstraZeneca, Abbvie, Beigene, Loxo, Newave, Genetech, Merck; Research Funding: Abbvie, Loxo, Verastem, Karyopharm, Morphosys, Schrodinger, Mingsight.
